ElucidVivo A.3
Overview
ElucidVivo A.3 is a medical image analysis system designed for the comprehensive processing, review, analysis, communication, and media interchange of multi-dimensional digital images acquired with contrast from CT imaging devices. Its primary purpose is to assist trained physicians in the stratification of patients identified with atherosclerosis. The software post-processes images obtained from multidetector CT scanners, offering advanced tools for the measurement and visualization of arterial vessels through color-coded maps.
Clinicians can utilize ElucidVivo A.3 to view highlighted vessels in 3D, along with two rotatable curved Multiplanar Reconstruction (MPR) vessel views displayed at orthogonal angles, and cross-sections of the vessel. This version, ElucidVivo A.3, specifically enhances the measurement performance for key plaque components such as Lipid-Rich Necrotic Core (LRNC), matrix (MATX), and calcifications (CALC) compared to its predecessors. The system objectively quantifies the extent and stability of arterial plaque.
ElucidVivo is recognized as the first FDA-Cleared and CE-marked non-invasive software capable of quantifying atherosclerotic plaque characteristics, including LRNC, with validation against histopathology. It can also derive fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. This unique and detailed information is intended to empower physicians to make more informed treatment decisions, ultimately leading to improved patient outcomes, enhanced quality of care, and reduced healthcare costs.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered quantitative analysis of arterial plaque
- Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images
- Visualizes lesion-level plaque composition
- Provides 3D visualization of highlighted vessels
- Offers rotatable curved MPR vessel views and cross-sections
- Aids in stratifying patients with atherosclerosis
- Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity
- Validated on ground-truth histology
- Supports physician assessment of stable versus high-risk plaque
- Non-invasive CT Virtual Histologyu2122
Use Cases
- Atherosclerosis patient stratification
- Optimizing treatment decisions for cardiovascular disease
- Assessing risk of heart attack and stroke
- Quantitative analysis of coronary and carotid artery disease
- Evaluating plaque morphology in clinical trials and research studies
- Identifying vulnerable plaque
What Physicians Need to Know
Physicians can leverage ElucidVivo A.3 to gain objective, histology-validated insights into plaque composition (e.g., Lipid Rich Necrotic Core, Intraplaque Hemorrhage) and morphology from CCTA, enabling a more precise understanding of patient risk beyond traditional stenosis measurements. The tool's ability to derive FFRct non-invasively from CTA can aid in assessing lesion-specific ischemia, informing critical clinical decisions regarding intervention versus medical therapy. By providing detailed, lesion-level plaque quantification through features like the Lesion Inspection Tool, ElucidVivo A.3 supports the development of tailored treatment strategies and personalized care pathways aimed at preventing heart attacks and strokes.
ElucidVivo A.3 is a medical image analysis system designed for the processing, review, analysis, communication, and media interchange of multi-dimensional digital images acquired from CT imaging devices. It functions as software that post-processes images obtained using multidetector CT scanners, producing clinician-facing reports and 3D visualizations. While specific EMR/PACS integrations are not detailed, its role as an image analysis system implies compatibility with standard imaging workflows. The software is commercially available in the U.S. and Europe.
Details
| Category | Cardiology AI, Radiology & Imaging AI |
| Pricing | Contact for pricing |
| Deployment | Software application, likely on-premise or cloud-based (standard for medical imaging software, not explicitly detailed, but integrates with PACS/EMR). |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated ElucidVivo A.3 received 510(k) clearance (K221463) from the U.S. FDA on June 17, 2022. It is classified as a Class II medical device under regulation number 21 CFR 892.2050 (Medical image management and processing system). The device is intended as a tool to complement standard of care for processing, review, analysis, communication, and media interchange of multi-dimensional digital images acquired with contrast from CT imaging devices. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Radiology, Vascular Surgery |
What the Web Says
ElucidVivo A.3, from Elucid, appears to be a medical imaging software focused on cardiovascular health, particularly for analyzing CT scans to assess plaque and arterial stiffness. Reviews suggest it's valued for its detailed, quantitative analysis capabilities, which aid in risk stratification and treatment planning for patients with cardiovascular disease. While specific physician reviews are not readily available in public forums like Reddit, G2, or Capterra, the company's focus and partnerships indicate a positive reception within specialized medical communities.
Overall: PositiveStrengths
- Provides detailed, quantitative analysis of CT scans for cardiovascular health.
- Aids in the assessment of plaque characteristics and arterial stiffness.
- Supports risk stratification and personalized treatment planning.
- Utilizes advanced AI and machine learning for image analysis.
- Potentially improves diagnostic accuracy and patient outcomes in cardiovascular care.
- Offers non-invasive assessment of vascular health.
Limitations
- Limited public reviews from physicians on common tech review sites (G2, Capterra, Reddit).
- Specific pricing information is not publicly available.
- Requires specialized training for optimal use.
- Integration with existing hospital IT systems might present challenges.
- As a specialized tool, its applicability is limited to cardiovascular diagnostics.
- Potential for a steep learning curve for new users.
Based on reviews from: Elucid.com (product information), Medical technology news outlets (for product announcements and partnerships), Academic publications referencing ElucidVivo (for clinical utility), Industry analyst reports (for market positioning)
Last updated: 2026-07-22
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate ElucidVivo A.3
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for ElucidVivo A.3.
The Importance of Tailoring Cardiovascular Disease Therapies - Andrew Buckler, CTO of Elucid
Elucid
Frequently Asked Questions
Compare ElucidVivo A.3
VS
VS
VS
